AZAYA has demonstrated the ability to utilize its proprietary PSL™ nanotechnology platform to formulate compounds for its own development pipeline. We are interested in exploring partnerships that will expand our proprietary technology platform to other drugs and agents.

To discuss a partnership opportunity, please contact Michael T. Dwyer, Chief Executive Officer of AZAYA Therapeutics at 210-341-6600 or by email at This e-mail address is being protected from spambots. You need JavaScript enabled to view it .

Prolonging Survival and Improving the Quality of Life Through Our Novel PSL™ Platform Technology